Abbott Laboratories vs Icl Group Ltd — how do they compare? Abbott Laboratories trades at $110.15 (market cap $187.95B), while Icl Group Ltd trades at $5.45 (market cap $6.94B). The key difference: Abbott Laboratories is far larger — about 27.1× Icl Group Ltd's market cap, and Icl Group Ltd pays the higher dividend (3.86%). Which is the better fit depends on your goals.
| ABT | ICL | |
|---|---|---|
Market Cap | $187.95B | $6.94B |
Sector | Health | Basic Materials |
52-Week High | $136.62 | $6.84 |
52-Week Low | $82.57 | $4.80 |
Enterprise Value | $214.96B | $9.58B |
Dividend Yield | 2.32% | 3.86% |
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $108.63, up 0.77% today, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, revenue grew to $44.33B in 2025 with a net income margin of 11.65%, while recent Q1 and Q2 2026 earnings beat expectations. The company maintains solid cash flow from operations of $9.57B and recently secured CE Mark for innovative dual glucose-ketone sensors, reinforcing its healthcare leadership.
Outlook remains positive with a consensus price target of $120.70, implying 11% upside, supported by 75.6% analyst buy ratings. Key risks include competitive pressures in diagnostics and macroeconomic sensitivity. The dividend yield and innovation pipeline offer stability, but investors should monitor execution on growth initiatives amid evolving market conditions.
ICL trades at $5.34, up 0.56% today, with a bullish technical signal supported by moving averages. Recent Q2 2026 earnings beat expectations with EPS of $0.12 versus $0.11 expected, continuing a trend of positive surprises. The company maintains stable cash flow from operations around $1.1B annually and pays consistent dividends, with recent payments of $0.05 and $0.06 per share.
Outlook remains cautious with 100% analyst hold ratings citing fair valuation. Risks include declining profit margins (3.95% net margin in 2025) and exposure to commodity price volatility. The stock offers moderate value with P/E of 22.25 and P/S of 0.89, but requires monitoring of cost transformation program effectiveness amid raw material inflation.
Trailing returns across standard periods
Latest headlines on both assets
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →